We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.09%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
-$3.15B
Cap. Flow
+$225M
Cap. Flow %
1.29%
Top 10 Hldgs %
85.01%
Holding
121
New
2
Increased
15
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
KOD icon
Kodiak Sciences
KOD
+$48.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
4
TSVT
2seventy bio
TSVT
+$20.9M
5
REPL icon
Replimune Group
REPL
+$19.2M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$20.1M
2
LEGN icon
Legend Biotech
LEGN
+$19M
3
OPT
Opthea Limited American Depositary Shares
OPT
+$3.19M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.43M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$6.76B 38.83%
46,912,266
+18,902
+0% +$2.56M
INCY icon
2
Incyte
INCY
$25.5B
$2.87B 16.5%
36,153,684
+2,535,621
+8% +$184M
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$2.2B 12.65%
11,668,897
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.43B
$1.02B 5.83%
41,910,704
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12B
$588M 3.38%
7,620,494
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$533M 3.06%
4,541,604
– –
ARGX icon
7
argenx
ARGX
$55.1B
$353M 2.03%
1,119,557
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.42B
$207M 1.19%
12,710,818
– –
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.5B
$147M 0.85%
1,499,213
– –
KOD icon
10
Kodiak Sciences
KOD
$2.4B
$123M 0.71%
15,931,045
+1,249,741
+9% +$48.8M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$116M 0.67%
1,409,784
– –
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$115M 0.66%
3,314,765
– –
ABCL icon
13
AbCellera Biologics
ABCL
$1.62B
$102M 0.59%
10,450,180
– –
KYMR icon
14
Kymera Therapeutics
KYMR
$8.61B
$101M 0.58%
2,384,742
– –
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$94.6M 0.54%
898,842
+299,732
+50% +$29.2M
TVTX icon
16
Travere Therapeutics
TVTX
$5.1B
$85M 0.49%
3,300,009
+630,955
+24% +$16.8M
IGMS
17
DELISTED
IGM Biosciences
IGMS
$84.4M 0.48%
3,156,102
– –
NVTA
18
DELISTED
Invitae Corporation
NVTA
$78.7M 0.45%
9,873,488
– –
IMCR icon
19
Immunocore
IMCR
$1.68B
$75.4M 0.43%
2,520,730
– –
CERS icon
20
Cerus
CERS
$577M
$75.3M 0.43%
13,713,195
– –
LEGN icon
21
Legend Biotech
LEGN
$3.64B
$73M 0.42%
2,008,999
-480,004
-19% -$19M
PRLD icon
22
Prelude Therapeutics
PRLD
$347M
$69.9M 0.4%
10,123,824
– –
AMRN
23
Amarin Corp
AMRN
$299M
$69.6M 0.4%
1,058,490
– –
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.2B
$63.5M 0.36%
676,975
– –
MRUS
25
DELISTED
Merus
MRUS
$53.9M 0.31%
2,037,469
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Baker Bros. Advisors held 121 positions worth $17.4B, down 15% from $20.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 4.1%. Baker Bros. Advisors opened 2 new positions and exited 3, leaving the 121-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2022 buy was Vera Therapeutics: 333,333 shares worth $7.83M.
  • Baker Bros. Advisors added most to Incyte in Q1 2022, an estimated $184M increase.
  • Baker Bros. Advisors's biggest Q1 2022 reduction was ChemoCentryx, Inc., cutting an estimated $20.1M.
  • Baker Bros. Advisors fully exited Albireo Pharma Inc in Q1 2022, selling an estimated $2.43M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $17.4B portfolio in Q1 2022.
  • Baker Bros. Advisors opened 2 new positions and closed 3 in Q1 2022.
  • Baker Bros. Advisors's portfolio value fell 15% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2022, filed 16 May 2022.